The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis

Joint, Bone, Spine : Revue Du Rhumatisme
Kwi Young KangSung-Hwan Park

Abstract

The aim was to access the effects of treatment on bone mineral density (BMD) by treatment agents in patients with ankylosing spondylitis (AS). We analyzed clinical characteristics of 90 AS patients. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and x-ray of lumbar spine (L-spine) and sacroiliac joint were included in the baseline assessment. The BMDs of right femur and L-spine were measured annually using dual x-ray absorptiometry (DXA). The patients were divided into one of the following four groups by agents exposed for the follow-up period: conventional treatment, bisphosphonate, anti-TNF-α agent or bisphosphonate + anti-TNF-α agent. We evaluated the changes of BMD according to treatment groups. The average age of disease onset was 30 years and the mean disease duration was 8.2 years. The patients who were assigned to the groups of conventional treatment, bisphosphonate, anti-TNF-α agents and bisphosphonate + anti-TNF-α agents were 40, 20, 19 and 11. BMDs values of both L-spine and femur showed tendencies to the most increase in the group treated with concurrent bisphosphonate and anti-TNF-α agent. However, the change of BMD by treatment agents was significant different only in trochanter (P = 0.001). In pat...Continue Reading

References

Aug 1, 1991·British Journal of Rheumatology·A Calin
Mar 3, 1990·BMJ : British Medical Journal·S H RalstonR D Sturrock
Apr 1, 1986·Calcified Tissue International·P H Stevenson, J R Stevenson
Mar 31, 1988·The New England Journal of Medicine·L G Raisz
Feb 1, 1994·Annals of the Rheumatic Diseases·S DonnellyT D Spector
May 1, 1993·Annals of the Rheumatic Diseases·H Franck, E Keck
Jan 1, 1996·Clinical Rheumatology·A SivriM Ariyurek
Aug 31, 2001·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J F MaillefertC Roux
Dec 13, 2002·Joint, Bone, Spine : Revue Du Rhumatisme·Birkan SonelNursen Düzgün
Aug 17, 2005·Current Drug Targets. Inflammation and Allergy·Yoshiya TanakaYosuke Okada
Sep 21, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·U LangeK L Schmidt
Sep 27, 2005·Clinical Endocrinology·Teoman AydinZerrin Sahin

❮ Previous
Next ❯

Citations

Jul 20, 2012·Current Opinion in Rheumatology·Vivian K KawaiMarie R Griffin
Aug 4, 2012·Therapeutic Advances in Musculoskeletal Disease·Charlotte L M Krieckaert, Willem F Lems
Aug 24, 2013·International Journal of Inflammation·José Francisco Zambrano-ZaragozaNorberto Vibanco-Pérez
Oct 1, 2015·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Kalliopi KlavdianouDimitrios Daoussis
Oct 25, 2014·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·D Prieto-AlhambraP Vestergaard
Feb 23, 2018·Calcified Tissue International·Alanna M DubrovskyNancy E Lane
May 3, 2012·American Journal of Therapeutics·Tommaso IannittiBeniamino Palmieri
Apr 11, 2014·Molecular Medicine Reports·Hyoju YiJi Hyeon Ju
Oct 7, 2010·Nature Reviews. Rheumatology·Rowan Higgs
Jun 13, 2020·British Journal of Clinical Pharmacology·Suzanne ArendsAnneke Spoorenberg
Jan 10, 2021·Archives of Osteoporosis·Shin-Hee KimKwi Young Kang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.